EN | TR
E-ISSN: 3061-9947
Evaluation of Patients with Essential Thrombosıtosis in Terms of Treatment Approaches and Clinical Properties
PDF
Cite
Share
Request
Original Article
VOLUME: 54 ISSUE: 1
P: 31-39
2021

Evaluation of Patients with Essential Thrombosıtosis in Terms of Treatment Approaches and Clinical Properties

Acta Haematol Oncol Turc 2021;54(1):31-39
DOI: 10.5505/aot.2021.22590
Cenk Sunu 1
Gülten Korkmaz Akat 2
Yasin Kalpakçı 1
Ahmet Kürşad Güneş 2
Simten Dağdaş 2
Funda Ceran 2
Gülsüm Özet 2
1. Department of Hematology, Sakarya University Training And Reaserch Hospital, Sakarya, Turkey
2. Department of Hematology, Ankara City Hospital, Ankara, Turkey
3.
No information available.
No information available
Received Date: 2020-05-17T18:34:25
Accepted Date: 2021-04-07T09:21:27
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Thrombocytosis,leukocytosis,and a small risk of disease progression into acute myeloid leukemia or myelofibrosis may be observed in essential thrombocythemia(ET).Aim of the study was to investigate sociodemographic and clinicopathologic characteristics of ET in Turkish sample.

METHODS

In this study,200 patients who were followed up with the diagnosis of ET between 2000-2013 were included.

RESULTS

121 (60.5%) of the patients were female,and 79 (39.5%) were male.The average age (±SD) was 54.93 (±14.21) years.The WBC (p<0.001),Hb (p<0.001) and platelet (p<0.001) values measured before the treatment were statistically significantly higher than the WBC,Hb and platelet values measured after the treatment.Hydroxyurea to 76 (38%),hydroxyurea+acetylsalicylic acid to 92 (46%),hydroxyurea+anagrelide to 1 (0.5%),acetylsalicylic acid to 15 (7.5%),3 (1.5%) interferon,1 (0.5%) interferon+acetylsalicylic acid,2 (1%) interferon+hydroxyurea,and 1 (0.5%) hydroxyurea+warfarin sodium treatment was started.Additional treatment was started in 92 (46%) of the cases,and was not started in 108 (54%).In total,54% of cases were treated with acetylsalicylic acid.There were 7 (3.5%) cases who had thrombopheresis,and 193 (96.5%) cases did not.Treatment of 67 of the cases (33.5%) due to insufficient treatment,and 25 of them (12.5%) due to side effects was changed.There were 7 (3.5%) cases with myelofibrosis/acute leukemia transformation,and 193 (96.5%) cases without.Only 4 (2%) of the cases had a history of seconder malignancy.

DISCUSSION AND CONCLUSION

It was similar in terms of age and gender with previous studies.It was observed that the WBC values of the cases decreased significantly after the treatment.In previous studies,the decrease in Hb value achieved with treatment was similar in our study.It was determined that there was a significant decrease in platelet levels of ET cases with treatment.Cytoreductive treatment was preferred in high-risk cases and antiplatelet treatment was preferred in the low-risk group.Hydroxyurea treatment was discontinued or anegrelid treatment was initiated in those who did not respond with hydroxyurea treatment and/or were unable to tolerate this treatment or observed undesirable events.